千亿qy

Be the most trusted biotech company

2025-12-30

Henlius Marks Innovation-Driven Milestone with Three Concurrent IND Acceptances
2025-12-30

Henlius Doses First Patient in Phase 1 Trial of Novel PD-1xVEGF Bispecific Antibody HLX37 for Solid Tumors
2025-12-25

Henlius Debuts HLX43 Phase 2 ESCC Data at ASCO GI, Alongside Updates on Serplulimab and Novel Epitope HER2 mAb HLX22
2025-12-23

Henlius CEO Dr. Jason Zhu to Deliver a Keynote Presentation at JPM 2026
2025-12-19

U.S. FDA Clearance of IND for Nivolumab Biosimilar HLX18
2025-12-16

Real-World Data of Serplulimab in Small-cell Lung Cancer Patients with Brain Metastases Presented at ESMO IO 2025
2025-12-12

China NMPA Accepts NDA and Grants Priority Review to Serplulimab for Neo-/Adjuvant Treatment of Gastric Cancer
2025-12-10

Henlius Highlights Dual Progress in Breast Cancer Pipeline as HLX11 and HLX78 Data Release at ESMO Asia 2025
2025-12-09

The LATAM Investigator Meeting for the Head-to-Head Trial of HLX22 Versus Pembrolizumab Successfully Held in Brazil